Sequent scientific posts robust q2 fy26 growth, boosted by merger

Sequent Scientific Limited announced a significant increase in its financial performance for Q2 FY26 and H1 FY26. For Q2 FY26, the company reported revenues of ₹4,240m, a 15% year-over-year (YoY) increase. EBITDA surged by 47% YoY to ₹657m, with the EBITDA margin expanding by 330 basis points (bps) to 15.5%. Profit After Tax (PAT) saw a remarkable 209.4% YoY rise, reaching ₹196m.

The company's Formulations segment recorded an 18% YoY growth in Q2 FY26, reaching ₹3,351m, with notable performance in Europe and Emerging Markets. The APIs segment also grew by 7% YoY to ₹830m. For H1 FY26, Sequent's revenues grew by 14% YoY to ₹8,654m, with EBITDA increasing by 35.4% YoY to ₹1,259m, and PAT rising by 141.3% YoY to ₹372m.

The merger with Viyash Life Sciences is nearing completion, with NCLT approval order reserved on October 31, 2025. Combined Q2 FY26 performance shows revenues of ₹8,521m, a 16.3% combined YoY growth, and a combined EBITDA of ₹1,890m, marking a 76% combined YoY growth. The net debt to LTM EBITDA improved to 0.7x from 1.4x in Q2 FY25. Synergies from the merger are already evident in manufacturing and R&D.